Angelini Ventures
Angelini Ventures co-leads €84 Million Series B investment in NUCLIDIUM's revolutionary cancer theranostic platform
Angelini Ventures has co-led a CHF 79 million (€84 million) Series B financing round for NUCLIDIUM, a clinical-stage biotechnology company pioneering copper-based radiopharmaceuticals for cancer diagnosis and treatment.
The innovative Swiss company leverages Copper-61 for diagnostics and Copper-67 for therapeutics, creating a differentiated theranostic platform that addresses critical limitations in current radiotheranostics.
We are pleased to have co-led this financing in NUCLIDIUM alongside other high-quality European investors. At Angelini Ventures we continue to identify and invest in companies that pursue scientifically differentiated opportunities with a clear path to address unmet needs.
Regina Hodits,
Early clinical trials have demonstrated superior cancer detection capabilities compared to existing approved methods, marking a significant step forward in precision oncology.
The funding will accelerate clinical development across multiple oncology indications while expanding NUCLIDIUM's global production and manufacturing network.
Read the full news: